S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:IOVA

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

$7.98
-0.15 (-1.85%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.91
$8.15
50-Day Range
$5.62
$8.16
52-Week Range
$5.42
$18.73
Volume
2.66 million shs
Average Volume
5.10 million shs
Market Capitalization
$1.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.50

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
144.4% Upside
$19.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
0.55mentions of Iovance Biotherapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$65.19 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.48) to ($2.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

66th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

12th out of 168 stocks

IOVA stock logo

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

Iovance And Its Struggle To Bring TIL Therapy To Market
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
Iovance Biotherapeutics Recent Insider Activity
Iovance Declines Following FDA Feedback On Its Melanoma Drug Lifileucel
Robert W. Baird Keeps Their Buy Rating on SAB Biotherapeutics (SABS)
Recap: Iovance Biotherapeutics Q3 Earnings
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings
11/04/2021
Today
2/04/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
319
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$19.50
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+144.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

Net Income
$-342,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.96 per share

Miscellaneous

Free Float
145,845,000
Market Cap
$1.26 billion
Optionable
Optionable
Beta
0.20

Social Links


Key Executives

  • Frederick G. Vogt
    President, CEO, Secretary & General Counsel
  • Igor P. Bilinsky
    Chief Operating Officer
  • Jean-Marc Bellemin
    CFO & Principal Accounting Officer
  • Friedrich Graf Finckenstein
    Chief Medical Officer
  • Kristin Lanzi
    Vice President-Information Technology













IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price forecast for 2023?

11 equities research analysts have issued 12-month price targets for Iovance Biotherapeutics' shares. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they anticipate the company's stock price to reach $19.50 in the next year. This suggests a possible upside of 144.4% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2023?

Iovance Biotherapeutics' stock was trading at $6.39 at the beginning of the year. Since then, IOVA shares have increased by 24.9% and is now trading at $7.98.
View the best growth stocks for 2023 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) posted its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.02. During the same period last year, the company posted ($0.40) EPS.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.64%), Rice Hall James & Associates LLC (1.15%), Bank of Montreal Can (1.08%), C WorldWide Group Holding A S (0.86%), ARK Investment Management LLC (0.52%) and New York State Common Retirement Fund (0.37%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $7.98.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.26 billion. The biotechnology company earns $-342,250,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

The company employs 319 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 2/5/2023 by MarketBeat.com Staff